Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for maintenance of remission after withdrawal of steroids and immunosuppressants in steroid-dependent or multirelapsing nephrotic syndrome
2008-006750-17Phase 3Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in nephrosis and focal segmental glomerulosclerosis (FSGS), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Recurrence of nephrotic syndrome. Started Jan 2009; status: completed.
02
Drugs
rituximab
03
Conditions
nephrosisfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2008-006750-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006750-17.